New gene therapy aims to fix protein deficiency in lung and liver disease
Disease control
Not yet recruiting
This study tests a new treatment called TSRA-196 for people with a severe form of Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can damage the lungs and liver. The therapy is designed to help the body produce more of the protective protein it is missing. The tri…
Phase: PHASE1, PHASE2 • Sponsor: Tessera Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC